Table 4 Interaction between metformin and subgroups on mortality outcomes
Subgroups | β-coefficient for the interaction with metformin and mortality [95% CI] | P-value | R-squared |
|---|---|---|---|
Female Gender | 4.9 [3.7–6.1] | < 0.001 | 0.993 |
LVEF≥50% | − 2.3 [− 3.3, − 1.3] | 0.003 | 0.954 |
LVEF < 50% | 0.2 [− 0.2, 0.6] | 0.279 | 0.863 |
CAD | − 2.0 [− 10.3, 6.2] | 0.530 | 0.801 |
PVD | − 3.4 [− 4.4, − 2.3] | 0.001 | 0.969 |
Hypertension | − 1.4 [− 2.8, 0.1] | 0.060 | 0.909 |
ACEi/ARB | − 1.1 [− 1.3, − 0.8] | < 0.001 | 0.974 |
Beta blocker | − 1.6 [− 2.7, − 0.5] | 0.017 | 0.934 |
Insulin | − 1.8 [− 2.5, − 1.0] | 0.002 | 0.958 |
Sulfonylurea | 2.7 [− 0.5, 5.9] | 0.077 | 0.915 |
Metformin treatment adjusted for LVEF, ACEi/ARB and beta-blocker therapy | − 0.2 [− 0.3, − 0.1] | 0.020 | 0.996 |